Janssen Biotech, a Johnson & Johnson company, submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its single dose COVID-19 vaccine. The submission is based on topline safety and efficacy data from the Phase III ENSEMBLE clinical trial. If the FDA grants the EUA, with the expected response at the end of February, it will mark the first single dose vaccine approved globally.

Read more here.